14.04.2016 • NewsDede WillamsoncologyMerck

Maya Martinez-Davis to Head Oncology at Merck KGaA

With immediate effect, Merck KGaA has appointed Maya Martinez-Davis (46) as global head of oncology for its biopharma business, succeeding Andrew Schiermeier. She will be based in Billerica, Massachusetts, USA, and report to Rehan Verjee, chief marketing and strategy officer of Merck’s Healthcare business.

The new appointee’s responsibilities will include defining integrated global oncology strategies and delivery of therapeutic launches, starting with Avelumab, an investigational anti-PD-L1 antibody initially discovered and developed by Merck and currently managed under a strategic alliance with Pfizer

Before joining Merck, Martinez-Davis was a senior executive with Pfizer for more than a decade and prior to that held senior-level and director-level positions with Aventis Pharma in oncology.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.